Editorial: PPARs: A double-edged sword in cancer Therapy?

PPAR Research

Volumn , Issue , 2008, Pages

  Panigrahy, Dipak ^a,b   Kaipainen, Arja ^c   Kieran, Mark W ^a,b   Huang, Sui ^d  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF CALGARY   (Canada)

^d UNIVERSITY OF CALGARY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ANTAGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; ROSIGLITAZONE;

CANCER INHIBITION; CANCER RESEARCH; CANCER THERAPY; CARCINOGENESIS; CELL METABOLISM; CELL PROLIFERATION; EDITORIAL; HUMAN; LIPOSARCOMA; LIVER CARCINOGENESIS; PROSTATE CANCER; TUMOR GROWTH;

EID: 68149170011     PISSN: 16874757     EISSN: 16874765     Source Type: Journal    
DOI: 10.1155/2008/350351     Document Type: Editorial

References (2)

1. Vogelstein B., Kinzler K. W., The multistep nature of cancer Trends in Genetics 1993 9 4 138 141
2. Peters J. M., Cattley R. C., Gonzalez F. J., Role of PPAR in the mechanism of action of the nongenotoxic carcinogen and peroxisome proliferator Wy-14,643 Carcinogenesis 1997 18 11 2029 2033